A Phase 3 interventional study of Cabotegravir - Injectable Suspension (CAB LA) and Rilpivirine - Injectable Suspension (RPV LA) in Human Immunodeficiency Virus Type 1 (HIV-1), sponsored by ViiV Healthcare. Completed at 30 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-26.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will assess the pharmacokinetics, safety, tolerability, maintenance of virological suppression and patient reported outcomes for participants receiving CAB and RPV LA injections following SC administration in the anterior abdominal wall SC tissue compared with IM administration in the gluteus medius muscle in adult participants living with HIV-1 infection in the FLAIR study (NCT02938520).
3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
This study's enrollment of 94 is close to the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female Participants: A female participant is eligible to participate if she is not pregnant at Screening and first day of Induction Phase (as confirmed by a negative serum human chorionic gonadotrophin [hCG] test), not lactating, and at least one of the following conditions applies
Non- defined as:
Exclusion Criteria:
Evidence of virus (HBV) infection based on the results of testing at Screening for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti HBc), Hepatitis B surface antibody (anti-HBs) and HBV Deoxyribonucleic acid (DNA) as follows:
Asymptomatic individuals with chronic virus (HCV) infection will not be excluded, however Investigators must carefully assess if therapy specific for HCV infection is required; participants who are anticipated to require HCV treatment prior to Week 48 of the Maintenance Phase must be excluded. HCV treatment on study may be permitted post Week 48, following consultation with the Medical Monitor. Participants with HCV co-infection will be allowed entry into Phase 3 studies if:
Treatment with any of the following agents within 28 days of Screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received an intramuscular (IM) injection of CAB LA 400 mg and RPV LA 600 mg on week -4 during the Screening phase. Participants then received a sub-cutaneous (SC) injection of CAB LA 400 mg + RPV LA 600 mg on Day 1 of Week 1, Week 4 and Week 8 (once in every 4 weeks (Q4W)) for a total of 12 weeks during the SC abdominal Injection Phase. 4 weeks later, participants returned to the clinic for an IM gluteal injection (at Week 12) of CAB LA 400 mg + RPV LA 600 mg during the Return to Gluteal Injection Phase and subsequent gluteal injection occurred after Q4W at Week 16.
Drug: Cabotegravir - Injectable Suspension (CAB LA) · Drug: Rilpivirine - Injectable Suspension (RPV LA)
It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.
It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
Concentrations at the End of the Dosing Interval (Ctau) of CAB LA 400 mg Following Administration CAB LA + RPV LA
Blood samples were collected at indicated time points for PK analysis.
Time frame: At screening Week-4; Day 1, Week 4, Week 8 for SC injections; and Week 12 for Return to IM gluteal injection
Ctau of RPV LA 600 mg Following Administration of CAB LA + RPV LA
Blood samples were collected at indicated time points for PK analysis.
Time frame: At screening Week-4; Day 1, Week 4, Week 8 for SC abdominal injections; and Week 12 for Return to IM gluteal injection
Maximum Plasma Concentration (Cmax) One Week Post Dose of CAB LA 400 mg Following Administration of CAB LA + RPV LA
Blood samples were collected at indicated time points for PK analysis.
Time frame: At screening week -3; Week 1, Week 5, Week 9 for SC abdominal injections; and Week 13 for Return to IM gluteal injection
Cmax One Week Post Dose of RPV LA 600 mg Following Administration of CAB LA + RPV LA
Blood samples were collected at indicated time points for PK analysis.
Time frame: At screening Week -3; Week 1, Week 5, Week 9 for SC abdominal injections; and Week 13 for Return to IM gluteal injection
Area Under the Plasma Concentration-time Curve From 0 Through the End of Dosing Interval (AUC[0-tau]) of CAB LA 400 mg Following Administration of CAB LA + RPV LA
Blood samples were collected at indicated time points for PK analysis.
Time frame: At screening Week-4; Day 1, Week 4, Week 8 for SC abdominal injections; and Week 12, for Return to IM gluteal injection
AUC[0-tau] of RPV LA 600 mg Following Administration of CAB LA + RPV LA
Blood samples were collected at indicated time points for PK analysis.
Time frame: At screening Week-4; Day 1, Week 4, Week 8 for SC abdominal injections; and Week 12 for Return to IM gluteal injection
Number of Participants With Injection Site Reactions (ISRs) and by Maximum Severity - SC Injection Phase
Severity of ISRs was analyzed using division of acquired immunodeficiency syndrome (DAIDS) grading scale. The severity is categorized into grades as following: Grade 1 - mild, Grade 2 - moderate, Grade 3 - severe, Grade 4 - Potentially life threatening, Grade 5 - Death. Higher grade indicates more severe condition.
Time frame: From Day 1 Up to Week 12
Number of Participants With Adverse Events of Special Interest (AESI) Based on Maximum Severity Grade - SC Injection Phase
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Severity of AESI was analyzed using DAIDS grading scale. The severity is categorized into grades as following: Grade 1 - mild, Grade 2 - moderate, Grade 3 - severe, Grade 4 - Potentially life threatening, Grade 5 - Death. Higher grade indicates more severe condition. AESI assessed were Depression, Anxiety, Impact on creatinine, Hyperglycaemia.
Time frame: From Day 1 Up to Week 12
Number of Participants Who Discontinue Treatment Due to ISRs and AESIs - SC Injection Phase
Time frame: From Day 1 Up to Week 12
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From the Last IM Gluteal Injection in Screening Phase to the End of the SC Injection Phase
SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs.
Time frame: From Week -4 Up to Week 12
Change From Baseline in Chemistry Parameters Following Administration of SC Injection: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), and Creatine Phosphokinase
Blood samples were collected as assessed by protocol, at specific time points for the analysis of clinical chemistry parameters. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
Time frame: Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12
Change From Baseline in Chemistry Parameters Following Administration of SC Injection: Creatinine, Total Bilirubin
Time frame: Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12
Change From Baseline in Chemistry Parameters Following Administration of SC Injection: Glucose, Potassium, Sodium, Blood Urea Nitrogen, Carbon Dioxide, Chloride, Phosphate
Time frame: Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12
Change From Baseline in Chemistry Parameter Following Administration of SC Injection: Albumin
Time frame: Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12
Change From Baseline in Chemistry Parameters Following Administration of SC Injection: Lipase
Time frame: Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12
Change From Baseline in Chemistry Parameters Following Administration of SC Injection: Creatinine Clearance
Time frame: Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12
Change From Baseline in Fasting Lipid Panels Following Administration of SC Injection: Total Cholesterol, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Triglycerides
Time frame: Baseline (screening Week -4), and CFB at Week 12
Change From Baseline in Hematology Parameters Following Administration of SC Injection: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelet Count
Blood samples were collected as assessed by protocol, at specific time points for the analysis of hematology parameters. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
Time frame: Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12
Change From Baseline in Hematology Parameter Following Administration of SC Injection: Red Blood Cell (RBC) Count
Time frame: Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12
Change From Baseline in Hematology Parameter Following Administration of SC Injection: Hemoglobin
Time frame: Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12
Change From Baseline in Hematology Parameter Following Administration of SC Injection: Hematocrit
Time frame: Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12
Change From Baseline in Hematology Parameter Following Administration of SC Injection: Mean Corpuscular Volume
Time frame: Baseline (screening Week -4), Change from baseline (CFB) at Week 4, CFB at Week 8, and CFB at Week 12
Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) Less Than (<) 50 Copies Per Milliliter (c/mL) Using the Food and Drug Administration (FDA) Snapshot Algorithm - SC Injection Phase
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12
Percentage of Participants With Plasma HIV RNA Greater Than Equal to (>=) 50 c/mL as Per FDA Snapshot Algorithm - SC Injection Phase
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12
Percentage of Participants With Protocol Defined Confirmed Virologic Failure (CVF) of >=200 c/mL - SC Injection Phase
Plasma samples were collected for quantitative analysis of HIV-1 RNA. CVF was defined as rebound as indicated by two consecutive plasma HIV-1-RNA levels \>=200 c/mL after prior suppression to \<200 c/mL.
Time frame: From Day 1 Up to Week 12
Number of Participants With Treatment Emergent Phenotypic Resistance - SC Injection Phase
Plasma samples were collected for drug resistance testing. Number of participants who met CVF criteria (two consecutive plasma HIV-1-RNA levels \>=200 copies/mL after prior suppression to \<200 copies/mL) with treatment emergent phenotypic resistance were reported.
Time frame: From Day 1 Up to Week 12
Number of Participants With Treatment Emergent Genotypic Resistance - SC Injection Phase
Plasma samples were collected for drug resistance testing. Number of participants who met CVF criteria (two consecutive plasma HIV-1-RNA levels \>=200 copies/mL after prior suppression to \<200 copies/mL) with treatment emergent genotypic resistance were reported.
Time frame: From Day 1 Up to Week 12
Number of Participants With Post-injection Pain Assessment Using Numeric Rating Scale (NRS) on Week-3 - Screening/IM Gluteal Injection Phase
A numeric rating scale was used to assess the level of pain experienced following injections with CAB + RPV. The scale contains one item and the response scale is ranging from 0= "no pain" to 10= "extreme pain". NRS questionnaire included the question regarding the maximum level of pain experienced with the most recent injections. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).
Time frame: Week -3 (Baseline)
Number of Participants With Post-injection Pain Assessment Using Numeric Rating Scale (NRS) on Week 1 - SC Injection Phase
A numeric rating scale was used to assess the level of pain experienced following injections with CAB + RPV. The scale contains one item and the response scale is ranging from 0= "no pain" to 10= "extreme pain". NRS questionnaire included the question regarding the maximum level of pain experienced with the most recent injections. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).
Time frame: Day 1
Number of Participants With Post-injection Pain Assessment Using NRS on Week 9- SC Injection Phase
A numeric rating scale was used to assess the level of pain experienced following injections with CAB + RPV. The scale contains one item and the response scale is ranging from 0= "no pain" to 10= "extreme pain". NRS questionnaire included the questions regarding the maximum level of pain experienced with the most recent injections. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).
Time frame: Week 9
Number of Participants With Post-injection Pain Assessment Using NRS on Week 13- Return to IM Gluteal Injection Phase
A numeric rating scale was used to assess the level of pain experienced following injections with CAB + RPV. The scale contains one item and the response scale is ranging from 0= "no pain" to 10= "extreme pain". NRS questionnaire included the questions regarding the maximum level of pain experienced with the most recent injections. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).
Time frame: Week 13
HIV Treatment Satisfaction Questionnaire - Status Version (HIVTSQs) Total Score -Screening/IM Gluteal Injection Phase
HIVTSQ is a self-completion measure specifically designed to measure treatment satisfaction in HIV participants. HIVTSQs questionnaire includes 12 questions and the total treatment satisfaction score is computed with items 1-11 and summed to produce a total score with a possible range of 0 to 66. Higher scores indicate a greater satisfaction and a lower score indicates dissatisfaction.
Time frame: Week -3 (Baseline)
HIVTSQs Total Score -SC Injection Phase
HIVTSQ is a self-completion measure specifically designed to measure treatment satisfaction in HIV participants. HIVTSQs questionnaire includes 12 questions and the total treatment satisfaction score is computed with items 1-11 and summed to produce a total score with a possible range of 0 to 66. Higher scores indicate a greater satisfaction and a lower score indicates dissatisfaction.
Time frame: At Week 9
HIVTSQs Total Score -Return to IM Gluteal Injection Phase
HIVTSQ is a self-completion measure specifically designed to measure treatment satisfaction in HIV participants. HIVTSQs questionnaire includes 12 questions and the total treatment satisfaction score is computed with items 1-11 and summed to produce a total score with a possible range of 0 to 66. Higher scores indicate a greater satisfaction and a lower score indicates dissatisfaction.
Time frame: At Week 17
Change From Baseline in HIVTSQs Individual Item Scores at Indicated Time Points -SC Injection Phase
HIVTSQs is a 12-item questionnaire and individual item scores on HIVTSQs scale are rated as 6 (very satisfied) to 0 (very dissatisfied). Higher scores represent greater satisfaction. Data was reported for each treatment satisfaction item based on the following items: Item 1=satisfaction with current treatment, Item 2=level of HIV control based on treatment, Item 3=any side effects of present treatment, Item 4=demands made by current treatment, Item 5=convenience in finding treatment, Item 6=flexibility in finding treatment, Item 7=understanding HIV, Item 8=extent to which the treatment fits in with lifestyle, Item 9=recommendation of present treatment to someone else, Item 10=continuation with present form of treatment, Item 11=easy or difficult treatment, Item 12=amount of discomfort/pain involved with present form of treatment.
Time frame: Baseline (Week -3) and up to Week 9
Change From Baseline in HIVTSQs Individual Item Scores at Indicated Time Points - Return to IM Gluteal Injection Phase
HIVTSQs is a 12-item questionnaire and individual item scores on HIVTSQs scale are rated as 6 (very satisfied) to 0 (very dissatisfied). Higher scores represent greater satisfaction. Data was reported for each treatment satisfaction item based on the following items: Item 1=satisfaction with current treatment, Item 2=level of HIV control based on treatment, Item 3=any side effects of present treatment, Item 4=demands made by current treatment, Item 5=convenience in finding treatment, Item 6=flexibility in finding treatment, Item 7=understanding HIV, Item 8=extent to which the treatment fits in with lifestyle, Item 9=recommendation of present treatment to someone else, Item 10=continuation with present form of treatment, Item 11=easy or difficult treatment, Item 12=amount of discomfort/pain involved with present form of treatment.
Time frame: Baseline (Week -3) and up to Week 17
Change From Study Week 9 to Study Week 17 in HIVTSQs Individual Item Scores at Indicated Time Points - Return to IM Gluteal Injection Phase
HIVTSQs is a 12-item questionnaire and individual item scores on HIVTSQs scale are rated as 6 (very satisfied) to 0 (very dissatisfied). Higher scores represent greater satisfaction. Data was reported for each treatment satisfaction item based on the following items: Item 1=satisfaction with current treatment, Item 2=level of HIV control based on treatment, Item 3=any side effects of present treatment, Item 4=demands made by current treatment, Item 5=convenience in finding treatment, Item 6=flexibility in finding treatment, Item 7=understanding HIV, Item 8=extent to which the treatment fits in with lifestyle, Item 9=recommendation of present treatment to someone else, Item 10=continuation with present form of treatment, Item 11=easy or difficult treatment, Item 12=amount of discomfort/pain involved with present form of treatment.
Time frame: Week 9 and Week 17
HIV Treatment Satisfaction Questionnaire - Change Version (HIVTSQc) Individual Item Score at Indicated Time Points -SC Injection Phase
HIVTSQc is a 12-item questionnaire to measure treatment satisfaction in HIV participants. Individual items were rated as +3 (much more satisfied) to -3(much less satisfied). Higher the score, greater the improvement in satisfaction with each aspect of treatment and lower the score, greater the deterioration in satisfaction with each aspect of treatment. Data was reported for each treatment satisfaction item based on the following items:Item 1=satisfaction with current treatment,Item2=level of HIV control based on treatment,Item3=any side effects of present treatment,Item4=demands made by current treatment,Item 5=convenience in finding treatment,Item 6=flexibility in finding treatment,Item 7=understanding HIV,Item 8=extent to which the treatment fits in with lifestyle,Item 9=recommendation of present treatment to someone else,Item 10=continuation with present form of treatment,Item 11=easy or difficult treatment,Item 12=amount of discomfort/pain involved with present form of treatment.
Time frame: From Week -4 up to Week 9
HIVTSQc Total Score at Indicated Time Points -SC Injection Phase
HIVTSQ is a self-completion measure specifically designed to measure treatment satisfaction in HIV participants. Total treatment satisfaction change score is computed using items 1 to 11 and are summed to produce a score with a possible range of -33 to 33. Higher the score, greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment. A score of 0 represented no change.
Time frame: From Week -4 up to Week 9
Perception of Injection (PIN) Questionnaire in Domain Scores and Individual Item Scores- Screening/IM Gluteal Injection Phase
The PIN questionnaire is characterized by the dimension scores based on 4 domains including Bother from injection site reactions (ISRs), Acceptability, Leg movement and Sleep categories. The objective of this endpoint is to present analysis of 2 (out of 4) PIN domains: Bother from ISRs and Acceptability. This questionnaire contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. Domain scores were calculated as a mean of all items with the domain. Scores range from 1 to 5,and questions are phrased in such a way as to ensure that 1 always equated with the most favorable perception of vaccination, and 5 the most unfavorable. Higher scores represent worse perception of injection. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).
Time frame: At Week -3 (Baseline)
PIN Questionnaire in Domain Scores and Individual Item Scores at Indicated Time Points - SC Injection Phase
The PIN questionnaire is characterized by the dimension scores based on 4 domains including Bother from injection site reactions (ISRs), Acceptability, Leg movement and Sleep categories. The objective of this endpoint is to present analysis of 2 (out of 4) PIN domains: Bother from ISRs and Acceptability. This questionnaire contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. Domain scores were calculated as a mean of all items with the domain. Scores range from 1 to 5,and questions are phrased in such a way as to ensure that 1 always equated with the most favorable perception of vaccination, and 5 the most unfavorable. Higher scores represent worse perception of injection. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).
Time frame: At Week 1 and Week 9
PIN Questionnaire in Domain Scores and Individual Item Scores - Return to IM Gluteal Injection Phase
The PIN questionnaire is characterized by the dimension scores based on 4 domains including Bother from injection site reactions (ISRs), Acceptability, Leg movement and Sleep categories. The objective of this endpoint is to present analysis of 2 (out of 4) PIN domains: Bother from ISRs and Acceptability. This questionnaire contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. Domain scores were calculated as a mean of all items with the domain. Scores range from 1 to 5,and questions are phrased in such a way as to ensure that 1 always equated with the most favorable perception of vaccination, and 5 the most unfavorable. Higher scores represent worse perception of injection. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).
Time frame: At Week 13
Change From Baseline to the PIN Questionnaire in Domain Scores and Individual Item Scores at Indicated Time Points - SC Injection Phase
The PIN questionnaire is characterized by the dimension scores based on 4 domains including Bother from injection site reactions (ISRs), Acceptability, Leg movement and Sleep categories. The objective of this endpoint is to present analysis of 2 (out of 4) PIN domains: Bother from ISRs and Acceptability. This questionnaire contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. Domain scores were calculated as a mean of all items with the domain. Scores range from 1 to 5,and questions are phrased in such a way as to ensure that 1 always equated with the most favorable perception of vaccination, and 5 the most unfavorable. Higher scores represent worse perception of injection. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).
Time frame: Change from Baseline (Week -3) at Week 1 and Week 9
Change From Baseline to the PIN Questionnaire in Domain Scores and Individual Item Scores at Indicated Time Points - Return to IM Gluteal Injection Phase
The PIN questionnaire is characterized by the dimension scores based on 4 domains including Bother from injection site reactions (ISRs), Acceptability, Leg movement and Sleep categories. The objective of this endpoint is to present analysis of 2 (out of 4) PIN domains: Bother from ISRs and Acceptability. This questionnaire contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. Domain scores were calculated as a mean of all items with the domain. Scores range from 1 to 5,and questions are phrased in such a way as to ensure that 1 always equated with the most favorable perception of vaccination, and 5 the most unfavorable. Higher scores represent worse perception of injection. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).
Time frame: Change from Baseline (Week -3) at Week 13
Number of Participants With Their Treatment Preference Assessed Using Preference Questionnaire on Week 9 - SC Injection Phase
A preference questionnaire was used to assess participant's preference for the subcutaneous injections compared with the gluteal injections. The "Preference" questionnaire included a single item question evaluating preference of HIV treatment. Participants were required to provide their response to Question, which stated "Which injection site do you prefer". The responses included Intramuscular Injections in the buttock, Subcutaneous Injections in the Abdomen and No preference.
Time frame: Up to Week 9
Number of Participants With Their Treatment Preference Assessed Using Preference Questionnaire on Week 17 - Return to IM Gluteal Injection Phase
A preference questionnaire was used to assess participant's preference for the subcutaneous injections compared with the gluteal injections. The "Preference" questionnaire included a single item question evaluating preference of HIV treatment. Participants were required to provide their response to Question, which stated "Which injection site do you prefer". The responses included Intramuscular Injections in the buttock, Subcutaneous Injections in the Abdomen and No preference.
Time frame: Up to Week 17
| Milestone | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Started | 94 |
| Completed | 93 |
| Not completed | 1 |
| Withdrew: Passed away due to unknown reasons | 1 |
| Milestone | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Started | 93 |
| Completed | 87 |
| Not completed | 6 |
| Withdrew: Adverse event | 2 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Withdrawal by subject | 3 |
| Milestone | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Started | 87 |
| Completed | 86 |
| Not completed | 1 |
| Withdrew: Protocol violation | 1 |
Blood samples were collected at indicated time points for PK analysis.
| microgram per milliliter (µg/mL) | CAB+RPV Screening Gluteal Injection | CAB+RPV First Sub-Cutaneous (SC) Injection | CAB+RPV Second SC Injection | CAB+RPV Last SC Injection | CAB+RPV Return to Intramuscular (IM) Gluteal Injection |
|---|---|---|---|---|---|
| Concentrations at the End of the Dosing Interval (Ctau) of CAB LA 400 mg Following Administration CAB LA + RPV LA | 2.759 ± 36.64 | 2.670 ± 37.02 | 2.607 ± 39.00 | 2.632 ± 38.87 | 2.797 ± 36.18 |
Blood samples were collected at indicated time points for PK analysis.
| Nanograms per milliliter (ng/mL) | CAB+RPV Screening Gluteal Injection | CAB+RPV First Sub-Cutaneous (SC) Injection | CAB+RPV Second SC Injection | CAB+RPV Last SC Injection | CAB+RPV Return to Intramuscular (IM) Gluteal Injection |
|---|---|---|---|---|---|
| Ctau of RPV LA 600 mg Following Administration of CAB LA + RPV LA | 137.021 ± 38.51 | 138.611 ± 36.43 | 135.620 ± 35.55 | 128.590 ± 39.71 | 139.879 ± 43.06 |
Blood samples were collected at indicated time points for PK analysis.
| µg/mL | CAB+RPV Screening Gluteal Injection | CAB+RPV First Sub-Cutaneous (SC) Injection | CAB+RPV Second SC Injection | CAB+RPV Last SC Injection | CAB+RPV Return to Intramuscular (IM) Gluteal Injection |
|---|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) One Week Post Dose of CAB LA 400 mg Following Administration of CAB LA + RPV LA | 3.545 ± 34.77 | 3.316 ± 35.22 | 3.165 ± 36.77 | 3.215 ± 34.56 | 3.529 ± 37.05 |
Blood samples were collected at indicated time points for PK analysis.
| ng/mL | CAB+RPV Screening Gluteal Injection | CAB+RPV First Sub-Cutaneous (SC) Injection | CAB+RPV Second SC Injection | CAB+RPV Last SC Injection | CAB+RPV Return to Intramuscular (IM) Gluteal Injection |
|---|---|---|---|---|---|
| Cmax One Week Post Dose of RPV LA 600 mg Following Administration of CAB LA + RPV LA | 162.287 ± 35.73 | 152.614 ± 36.56 | 148.051 ± 35.27 | 149.145 ± 36.91 | 154.659 ± 36.38 |
Blood samples were collected at indicated time points for PK analysis.
| hour microgram per milliliter (h*µg/mL) | CAB+RPV Screening Gluteal Injection | CAB+RPV First Sub-Cutaneous (SC) Injection | CAB+RPV Second SC Injection | CAB+RPV Last SC Injection | CAB+RPV Return to Intramuscular (IM) Gluteal Injection |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From 0 Through the End of Dosing Interval (AUC[0-tau]) of CAB LA 400 mg Following Administration of CAB LA + RPV LA | 2051.172 ± 34.31 | 1997.801 ± 33.94 | 1943.596 ± 35.25 | 1943.787 ± 35.53 | 2155.520 ± 32.71 |
Blood samples were collected at indicated time points for PK analysis.
| h*µg/mL | CAB+RPV Screening Gluteal Injection | CAB+RPV First Sub-Cutaneous (SC) Injection | CAB+RPV Second SC Injection | CAB+RPV Last SC Injection | CAB+RPV Return to Intramuscular (IM) Gluteal Injection |
|---|---|---|---|---|---|
| AUC[0-tau] of RPV LA 600 mg Following Administration of CAB LA + RPV LA | 98003.488 ± 34.31 | 98801.696 ± 35.32 | 95743.414 ± 34.56 | 93248.069 ± 34.85 | 100006.767 ± 34.78 |
Severity of ISRs was analyzed using division of acquired immunodeficiency syndrome (DAIDS) grading scale. The severity is categorized into grades as following: Grade 1 - mild, Grade 2 - moderate, Grade 3 - severe, Grade 4 - Potentially life threatening, Grade 5 - Death. Higher grade indicates more severe condition.
| Participants | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| ISRs | 85 |
| Mild or Grade 1 ISRs | 43 |
| Moderate or Grade 2 ISRs | 36 |
| Severe or Grade 3 ISRs | 6 |
| Potentially Life-Threatening or Grade 4 ISRs | 0 |
| Death or Grade 5 ISRs | 0 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Severity of AESI was analyzed using DAIDS grading scale. The severity is categorized into grades as following: Grade 1 - mild, Grade 2 - moderate, Grade 3 - severe, Grade 4 - Potentially life threatening, Grade 5 - Death. Higher grade indicates more severe condition. AESI assessed were Depression, Anxiety, Impact on creatinine, Hyperglycaemia.
| Participants | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Any Depression | 1 |
| Mild or Grade 1 Depression | 0 |
| Moderate or Grade 2 Depression | 1 |
| Severe or Grade 3 Depression | 0 |
| Potentially Life-Threatening or Grade 4 Depression | 0 |
| Death or Grade 5 Depression | 0 |
| Any Anxiety | 1 |
| Mild or Grade 1 Anxiety | 1 |
| Moderate or Grade 2 Anxiety | 0 |
| Severe or Grade 3 Anxiety | 0 |
| Potentially Life-Threatening or Grade 4 Anxiety | 0 |
| Death or Grade 5 Anxiety | 0 |
| Any Impact on Creatinine | 1 |
| Mild or Grade 1 Impact on Creatinine | 1 |
| Moderate or Grade 2 Impact on Creatinine | 0 |
| Severe or Grade 3 Impact on Creatinine | 0 |
| Potentially Life-Threatening or Grade 4 Impact on Creatinine | 0 |
| Death or Grade 5 Impact on Creatinine | 0 |
| Any Hyperglycaemia | 1 |
| Mild or Grade 1 Hyperglycaemia | 1 |
| Moderate or Grade 2 Hyperglycaemia | 0 |
| Severe or Grade 3 Hyperglycaemia | 0 |
| Potentially Life-Threatening or Grade 4 Hyperglycaemia | 0 |
| Death or Grade 5 Hyperglycaemia | 0 |
| Participants | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Discontinuations due to ISR | 5 |
| Discontinuations due to AESI | 0 |
SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs.
| Participants | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Any AEs | 90 |
| Any SAEs | 0 |
Blood samples were collected as assessed by protocol, at specific time points for the analysis of clinical chemistry parameters. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
| International units per liter (IU/L) | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| ALT, Baseline (screening Week -4) | 21.6 ± 10.38 |
| ALT, CFB at Week 4 | 1.2 ± 8.09 |
| ALT, CFB at Week 8 | -0.4 ± 5.94 |
| ALT, CFB at Week 12 | -0.7 ± 7.32 |
| ALP, Baseline (screening Week -4) | 62.3 ± 14.72 |
| ALP, CFB at Week 4 | -0.1 ± 7.51 |
| ALP, CFB at Week 8 | 0.7 ± 6.66 |
| ALP, CFB at Week 12 | -0.4 ± 6.29 |
| AST, Baseline (screening Week -4) | 20.1 ± 6.27 |
| AST, CFB at Week 4 | 2.2 ± 12.33 |
| AST, CFB at Week 8 | 0.1 ± 5.52 |
| AST, CFB at Week 12 | -0.2 ± 5.46 |
| Creatine phosphokinase, Baseline (screening Week -4) | 166.8 ± 163.38 |
| Creatine phosphokinase, CFB at Week 4 | 47.7 ± 340.57 |
| Creatine phosphokinase, CFB at Week 8 | 3.3 ± 206.30 |
| Creatine phosphokinase, CFB at Week 12 | -0.9 ± 162.90 |
| Micromoles per liter (umol/L) | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Creatinine, Baseline (screening Week -4) | 86.23 ± 14.551 |
| Creatinine, CFB at Week 4 | -1.84 ± 5.811 |
| Creatinine, CFB at Week 8 | -1.55 ± 8.224 |
| Creatinine, CFB at Week 12 | -0.35 ± 7.206 |
| Total Bilirubin, Baseline (screening Week -4) | 9.2 ± 4.01 |
| Total Bilirubin, CFB at Week 4 | 0.5 ± 3.52 |
| Total Bilirubin, CFB at Week 8 | -0.5 ± 3.64 |
| Total Bilirubin, CFB at Week 12 | -1.2 ± 3.21 |
| Millimoles per liter (mmol/L) | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Glucose, Baseline (screening Week -4) | 5.14 ± 0.808 |
| Glucose, CFB at Week 12 | -0.02 ± 0.571 |
| Potassium, Baseline (screening Week -4) | 4.19 ± 0.304 |
| Potassium, CFB at Week 4 | 0.02 ± 0.389 |
| Potassium, CFB at Week 8 | 0.03 ± 0.307 |
| Potassium, CFB at Week 12 | -0.04 ± 0.346 |
| Sodium, Baseline (screening Week -4) | 139.8 ± 1.81 |
| Sodium, CFB at Week 4 | -0.1 ± 1.72 |
| Sodium, CFB at Week 8 | 0.4 ± 2.11 |
| Sodium, CFB at Week 12 | 0.3 ± 1.91 |
| Blood Urea Nitrogen, Baseline (screening Week -4) | 5.33 ± 1.639 |
| Blood Urea Nitrogen, CFB at Week 4 | 0.13 ± 1.206 |
| Blood Urea Nitrogen, CFB at Week 8 | 0.22 ± 1.417 |
| Blood Urea Nitrogen, CFB at Week 12 | -0.04 ± 1.368 |
| Carbon Dioxide, Baseline (screening Week -4) | 23.6 ± 2.04 |
| Carbon Dioxide, CFB at Week 4 | -0.3 ± 2.09 |
| Carbon Dioxide, CFB at Week 8 | -0.6 ± 1.87 |
| Carbon Dioxide, CFB at Week 12 | -0.5 ± 1.83 |
| Chloride, Baseline (screening Week -4) | 103.7 ± 2.15 |
| Chloride, CFB at Week 4 | -0.3 ± 2.55 |
| Chloride, CFB at Week 8 | 0.6 ± 2.36 |
| Chloride, CFB at Week 12 | 0.5 ± 2.38 |
| Phosphate, Baseline (screening Week -4) | 1.103 ± 0.1651 |
| Phosphate, CFB at Week 4 | -0.002 ± 0.1836 |
| Phosphate, CFB at Week 8 | 0.023 ± 0.1731 |
| Phosphate, CFB at Week 12 | -0.015 ± 0.1570 |
| Grams per liter (g/L) | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Baseline (screening Week -4) | 43.1 ± 2.66 |
| CFB at Week 4 | 0.4 ± 2.56 |
| CFB at Week 8 | 0.8 ± 2.20 |
| CFB at Week 12 | -0.1 ± 2.11 |
| Units per liter (U/L) | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Baseline (screening Week -4) | 29.4 ± 17.69 |
| CFB at Week 4 | 0.3 ± 10.97 |
| CFB at Week 8 | 5.6 ± 25.61 |
| CFB at Week 12 | 1.4 ± 11.66 |
| Milliliter per minute (mL/min) | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Baseline (screening Week -4) | 93.9 ± 15.15 |
| CFB at Week 4 | 1.9 ± 6.95 |
| CFB at Week 8 | 1.8 ± 9.37 |
| CFB at Week 12 | 0.4 ± 8.06 |
| mmol/L | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Total Cholesterol, Baseline (screening Week -4) | 4.855 ± 0.9604 |
| Total Cholesterol, CFB at Week 12 | -0.073 ± 0.6056 |
| HDL Cholesterol, Baseline (screening Week -4) | 1.373 ± 0.3764 |
| HDL Cholesterol, CFB at Week 12 | -0.050 ± 0.1646 |
| LDL Cholesterol, Baseline (screening Week -4) | 2.899 ± 0.8464 |
| LDL Cholesterol, CFB at Week 12 | -0.040 ± 0.4786 |
| Triglycerides, Baseline (screening Week -4) | 1.299 ± 0.8672 |
| Triglycerides, CFB at Week 12 | 0.005 ± 0.5692 |
Blood samples were collected as assessed by protocol, at specific time points for the analysis of hematology parameters. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
| Giga cells per Liter (10^9 cells/L) | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Basophils, Baseline (screening Week -4) | 0.048 ± 0.0264 |
| Basophils, CFB at Week 4 | 0.000 ± 0.0274 |
| Basophils, CFB at Week 8 | -0.003 ± 0.0309 |
| Basophils, CFB at Week 12 | -0.002 ± 0.0343 |
| Eosinophils, Baseline (screening Week -4) | 0.193 ± 0.1648 |
| Eosinophils, CFB at Week 4 | 0.006 ± 0.1193 |
| Eosinophils, CFB at Week 8 | -0.033 ± 0.0981 |
| Eosinophils, CFB at Week 12 | -0.006 ± 0.1198 |
| Leukocytes, Baseline (screening Week -4) | 6.12 ± 1.901 |
| Leukocytes, CFB at Week 4 | 0.09 ± 1.524 |
| Leukocytes, CFB at Week 8 | -0.24 ± 1.364 |
| Leukocytes, CFB at Week 12 | -0.11 ± 1.210 |
| Lymphocytes, Baseline (screening Week -4) | 2.076 ± 0.6398 |
| Lymphocytes, CFB at Week 4 | 0.046 ± 0.4427 |
| Lymphocytes, CFB at Week 8 | -0.066 ± 0.4864 |
| Lymphocytes, CFB at Week 12 | -0.064 ± 0.4890 |
| Monocytes, Baseline (screening Week -4) | 0.470 ± 0.1897 |
| Monocytes, CFB at Week 4 | -0.006 ± 0.1204 |
| Monocytes, CFB at Week 8 | -0.053 ± 0.1284 |
| Monocytes, CFB at Week 12 | -0.044 ± 0.1448 |
| Neutrophils, Baseline (screening Week -4) | 3.328 ± 1.3927 |
| Neutrophils, CFB at Week 4 | 0.054 ± 1.3913 |
| Neutrophils, CFB at Week 8 | -0.093 ± 1.0953 |
| Neutrophils, CFB at Week 12 | 0.012 ± 0.9941 |
| Platelet Count, Baseline (screening Week -4) | 256.2 ± 70.85 |
| Platelet Count, CFB at Week 4 | -0.8 ± 33.28 |
| Platelet Count, CFB at Week 8 | -3.5 ± 30.93 |
| Platelet Count, CFB at Week 12 | 1.0 ± 36.35 |
| Trillion cells per liter (10^12/L) | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Baseline (screening Week -4) | 4.74 ± 0.398 |
| CFB at Week 4 | 0.03 ± 0.244 |
| CFB at Week 8 | 0.01 ± 0.248 |
| CFB at Week 12 | -0.04 ± 0.265 |
| Grams per liter (g/L) | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Baseline (screening Week -4) | 142.9 ± 12.14 |
| CFB at Week 4 | 0.3 ± 7.02 |
| CFB at Week 8 | -0.9 ± 6.87 |
| CFB at Week 12 | -2.4 ± 7.43 |
| Proportion of red blood cells in blood ( | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Baseline (screening Week -4) | 0.4268 ± 0.03402 |
| CFB at Week 4 | 0.0008 ± 0.02308 |
| CFB at Week 8 | 0.0014 ± 0.02243 |
| CFB at Week 12 | -0.0023 ± 0.02584 |
| Femtoliters (fL) | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Baseline (screening Week -4) | 90.2 ± 4.49 |
| CFB at Week 4 | -0.4 ± 1.74 |
| CFB at Week 8 | 0.2 ± 2.04 |
| CFB at Week 12 | 0.5 ± 2.51 |
| Percentage of participants | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Baseline (Day 1) | 100 (96 to 100) |
| Week 4 | 100 (96 to 100) |
| Week 8 | 99 (97 to 100) |
| Week 12 | 90 (84 to 96) |
| Percentage of participants | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Baseline (Day 1) | 0 (0.0 to 3.9) |
| Week 4 | 0 (0.0 to 4.0) |
| Week 8 | 1.1 (0.0 to 3.4) |
| Week 12 | 2.2 (0.0 to 5.1) |
Plasma samples were collected for quantitative analysis of HIV-1 RNA. CVF was defined as rebound as indicated by two consecutive plasma HIV-1-RNA levels \>=200 c/mL after prior suppression to \<200 c/mL.
| Percentage of participants | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Percentage of Participants With Protocol Defined Confirmed Virologic Failure (CVF) of >=200 c/mL - SC Injection Phase | 0 |
Plasma samples were collected for drug resistance testing. Number of participants who met CVF criteria (two consecutive plasma HIV-1-RNA levels \>=200 copies/mL after prior suppression to \<200 copies/mL) with treatment emergent phenotypic resistance were reported.
| Participants | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Number of Participants With Treatment Emergent Phenotypic Resistance - SC Injection Phase | 0 |
Plasma samples were collected for drug resistance testing. Number of participants who met CVF criteria (two consecutive plasma HIV-1-RNA levels \>=200 copies/mL after prior suppression to \<200 copies/mL) with treatment emergent genotypic resistance were reported.
| Participants | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Number of Participants With Treatment Emergent Genotypic Resistance - SC Injection Phase | 0 |
A numeric rating scale was used to assess the level of pain experienced following injections with CAB + RPV. The scale contains one item and the response scale is ranging from 0= "no pain" to 10= "extreme pain". NRS questionnaire included the question regarding the maximum level of pain experienced with the most recent injections. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).
| Participants | CAB Q4W | RPV Q4W |
|---|---|---|
| Individual item score 0 | 37 | 27 |
| Individual item score 1 | 21 | 16 |
| Individual item score 2 | 11 | 18 |
| Individual item score 3 | 7 | 9 |
| Individual item score 4 | 5 | 5 |
| Individual item score 5 | 1 | 6 |
| Individual item score 6 | 1 | 3 |
| Individual item score 7 | 6 | 4 |
| Individual item score 8 | 3 | 1 |
| Individual item score 9 | 0 | 1 |
| Individual item score 10 | 0 | 2 |
A numeric rating scale was used to assess the level of pain experienced following injections with CAB + RPV. The scale contains one item and the response scale is ranging from 0= "no pain" to 10= "extreme pain". NRS questionnaire included the question regarding the maximum level of pain experienced with the most recent injections. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).
| Participants | CAB Q4W | RPV Q4W |
|---|---|---|
| Individual Item Score 0 | 16 | 22 |
| Individual Item Score 1 | 13 | 19 |
| Individual Item Score 2 | 16 | 10 |
| Individual Item Score 3 | 8 | 13 |
| Individual Item Score 4 | 6 | 2 |
| Individual Item Score 5 | 6 | 7 |
| Individual Item Score 6 | 3 | 4 |
| Individual Item Score 7 | 10 | 7 |
| Individual Item Score 8 | 6 | 5 |
| Individual Item Score 9 | 7 | 2 |
| Individual Item Score 10 | 2 | 2 |
A numeric rating scale was used to assess the level of pain experienced following injections with CAB + RPV. The scale contains one item and the response scale is ranging from 0= "no pain" to 10= "extreme pain". NRS questionnaire included the questions regarding the maximum level of pain experienced with the most recent injections. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).
| Participants | CAB Q4W | RPV Q4W |
|---|---|---|
| Individual Item Score 0 | 21 | 19 |
| Individual Item Score 1 | 9 | 11 |
| Individual Item Score 2 | 19 | 15 |
| Individual Item Score 3 | 9 | 13 |
| Individual Item Score 4 | 9 | 6 |
| Individual Item Score 5 | 4 | 7 |
| Individual Item Score 6 | 4 | 9 |
| Individual Item Score 7 | 3 | 3 |
| Individual Item Score 8 | 5 | 2 |
| Individual Item Score 9 | 4 | 0 |
| Individual Item Score 10 | 0 | 2 |
A numeric rating scale was used to assess the level of pain experienced following injections with CAB + RPV. The scale contains one item and the response scale is ranging from 0= "no pain" to 10= "extreme pain". NRS questionnaire included the questions regarding the maximum level of pain experienced with the most recent injections. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).
| Participants | CAB Q4W | RPV Q4W |
|---|---|---|
| Individual Item Score 0 | 40 | 41 |
| Individual Item Score 1 | 21 | 13 |
| Individual Item Score 2 | 10 | 12 |
| Individual Item Score 3 | 7 | 9 |
| Individual Item Score 4 | 3 | 3 |
| Individual Item Score 5 | 3 | 5 |
| Individual Item Score 6 | 0 | 2 |
| Individual Item Score 7 | 2 | 2 |
| Individual Item Score 8 | 1 | 0 |
| Individual Item Score 9 | 0 | 0 |
| Individual Item Score 10 | 0 | 0 |
HIVTSQ is a self-completion measure specifically designed to measure treatment satisfaction in HIV participants. HIVTSQs questionnaire includes 12 questions and the total treatment satisfaction score is computed with items 1-11 and summed to produce a total score with a possible range of 0 to 66. Higher scores indicate a greater satisfaction and a lower score indicates dissatisfaction.
| Scores on a scale | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| HIV Treatment Satisfaction Questionnaire - Status Version (HIVTSQs) Total Score -Screening/IM Gluteal Injection Phase | 62.15 ± 5.258 |
HIVTSQ is a self-completion measure specifically designed to measure treatment satisfaction in HIV participants. HIVTSQs questionnaire includes 12 questions and the total treatment satisfaction score is computed with items 1-11 and summed to produce a total score with a possible range of 0 to 66. Higher scores indicate a greater satisfaction and a lower score indicates dissatisfaction.
| Scores on a scale | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| HIVTSQs Total Score -SC Injection Phase | 51.99 ± 14.765 |
HIVTSQ is a self-completion measure specifically designed to measure treatment satisfaction in HIV participants. HIVTSQs questionnaire includes 12 questions and the total treatment satisfaction score is computed with items 1-11 and summed to produce a total score with a possible range of 0 to 66. Higher scores indicate a greater satisfaction and a lower score indicates dissatisfaction.
| Scores on a scale | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| HIVTSQs Total Score -Return to IM Gluteal Injection Phase | 62.71 ± 4.217 |
HIVTSQs is a 12-item questionnaire and individual item scores on HIVTSQs scale are rated as 6 (very satisfied) to 0 (very dissatisfied). Higher scores represent greater satisfaction. Data was reported for each treatment satisfaction item based on the following items: Item 1=satisfaction with current treatment, Item 2=level of HIV control based on treatment, Item 3=any side effects of present treatment, Item 4=demands made by current treatment, Item 5=convenience in finding treatment, Item 6=flexibility in finding treatment, Item 7=understanding HIV, Item 8=extent to which the treatment fits in with lifestyle, Item 9=recommendation of present treatment to someone else, Item 10=continuation with present form of treatment, Item 11=easy or difficult treatment, Item 12=amount of discomfort/pain involved with present form of treatment.
| Scores on a scale | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Item 1 | -1.2 ± 1.85 |
| Item 2 | -0.2 ± 0.79 |
| Item 3 | -1.5 ± 1.93 |
| Item 4 | -1.1 ± 1.67 |
| Item 5 | -1.2 ± 1.88 |
| Item 6 | -0.8 ± 1.83 |
| Item 7 | -0.2 ± 0.93 |
| Item 8 | -0.8 ± 1.59 |
| Item 9 | -1.1 ± 1.68 |
| Item 10 | -1.4 ± 1.97 |
| Item 11 | -1.0 ± 1.47 |
| Item 12 | -1.3 ± 1.79 |
HIVTSQs is a 12-item questionnaire and individual item scores on HIVTSQs scale are rated as 6 (very satisfied) to 0 (very dissatisfied). Higher scores represent greater satisfaction. Data was reported for each treatment satisfaction item based on the following items: Item 1=satisfaction with current treatment, Item 2=level of HIV control based on treatment, Item 3=any side effects of present treatment, Item 4=demands made by current treatment, Item 5=convenience in finding treatment, Item 6=flexibility in finding treatment, Item 7=understanding HIV, Item 8=extent to which the treatment fits in with lifestyle, Item 9=recommendation of present treatment to someone else, Item 10=continuation with present form of treatment, Item 11=easy or difficult treatment, Item 12=amount of discomfort/pain involved with present form of treatment.
| Scores on a scale | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Item 1 | 0.1 ± 0.43 |
| Item 2 | -0.1 ± 0.35 |
| Item 3 | 0.1 ± 0.72 |
| Item 4 | 0.0 ± 0.63 |
| Item 5 | 0.0 ± 0.55 |
| Item 6 | 0.0 ± 0.95 |
| Item 7 | 0.1 ± 0.55 |
| Item 8 | 0.0 ± 0.55 |
| Item 9 | 0.0 ± 0.32 |
| Item 10 | 0.1 ± 0.57 |
| Item 11 | 0.0 ± 0.58 |
| Item 12 | 0.2 ± 0.79 |
HIVTSQs is a 12-item questionnaire and individual item scores on HIVTSQs scale are rated as 6 (very satisfied) to 0 (very dissatisfied). Higher scores represent greater satisfaction. Data was reported for each treatment satisfaction item based on the following items: Item 1=satisfaction with current treatment, Item 2=level of HIV control based on treatment, Item 3=any side effects of present treatment, Item 4=demands made by current treatment, Item 5=convenience in finding treatment, Item 6=flexibility in finding treatment, Item 7=understanding HIV, Item 8=extent to which the treatment fits in with lifestyle, Item 9=recommendation of present treatment to someone else, Item 10=continuation with present form of treatment, Item 11=easy or difficult treatment, Item 12=amount of discomfort/pain involved with present form of treatment.
| Scores on a scale | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Item 1 | 1.3 ± 1.77 |
| Item 2 | 0.2 ± 0.77 |
| Item 3 | 1.6 ± 1.85 |
| Item 4 | 1.1 ± 1.60 |
| Item 5 | 1.2 ± 1.78 |
| Item 6 | 0.8 ± 1.41 |
| Item 7 | 0.2 ± 0.83 |
| Item 8 | 0.8 ± 1.40 |
| Item 9 | 1.0 ± 1.68 |
| Item 10 | 1.5 ± 1.97 |
| Item 11 | 1.0 ± 1.39 |
| Item 12 | 1.5 ± 1.88 |
HIVTSQc is a 12-item questionnaire to measure treatment satisfaction in HIV participants. Individual items were rated as +3 (much more satisfied) to -3(much less satisfied). Higher the score, greater the improvement in satisfaction with each aspect of treatment and lower the score, greater the deterioration in satisfaction with each aspect of treatment. Data was reported for each treatment satisfaction item based on the following items:Item 1=satisfaction with current treatment,Item2=level of HIV control based on treatment,Item3=any side effects of present treatment,Item4=demands made by current treatment,Item 5=convenience in finding treatment,Item 6=flexibility in finding treatment,Item 7=understanding HIV,Item 8=extent to which the treatment fits in with lifestyle,Item 9=recommendation of present treatment to someone else,Item 10=continuation with present form of treatment,Item 11=easy or difficult treatment,Item 12=amount of discomfort/pain involved with present form of treatment.
| Scores on a scale | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Item 1 | 0.7 ± 2.14 |
| Item 2 | 1.8 ± 1.40 |
| Item 3 | 0.5 ± 2.04 |
| Item 4 | 1.2 ± 1.75 |
| Item 5 | 1.0 ± 2.06 |
| Item 6 | 1.3 ± 1.76 |
| Item 7 | 2.0 ± 1.32 |
| Item 8 | 1.4 ± 1.77 |
| Item 9 | 1.3 ± 1.92 |
| Item 10 | 0.9 ± 2.11 |
| Item 11 | 1.2 ± 1.77 |
| Item 12 | 0.5 ± 2.18 |
HIVTSQ is a self-completion measure specifically designed to measure treatment satisfaction in HIV participants. Total treatment satisfaction change score is computed using items 1 to 11 and are summed to produce a score with a possible range of -33 to 33. Higher the score, greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment. A score of 0 represented no change.
| Scores on a scale | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| HIVTSQc Total Score at Indicated Time Points -SC Injection Phase | 13.4 ± 17.79 |
The PIN questionnaire is characterized by the dimension scores based on 4 domains including Bother from injection site reactions (ISRs), Acceptability, Leg movement and Sleep categories. The objective of this endpoint is to present analysis of 2 (out of 4) PIN domains: Bother from ISRs and Acceptability. This questionnaire contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. Domain scores were calculated as a mean of all items with the domain. Scores range from 1 to 5,and questions are phrased in such a way as to ensure that 1 always equated with the most favorable perception of vaccination, and 5 the most unfavorable. Higher scores represent worse perception of injection. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).
| Scores on a scale | CAB Q4W | RPV Q4W |
|---|---|---|
| Bother of ISRs | 1.44 ± 0.484 | 1.53 ± 0.568 |
| Acceptance | 1.51 ± 0.676 | 1.71 ± 0.781 |
The PIN questionnaire is characterized by the dimension scores based on 4 domains including Bother from injection site reactions (ISRs), Acceptability, Leg movement and Sleep categories. The objective of this endpoint is to present analysis of 2 (out of 4) PIN domains: Bother from ISRs and Acceptability. This questionnaire contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. Domain scores were calculated as a mean of all items with the domain. Scores range from 1 to 5,and questions are phrased in such a way as to ensure that 1 always equated with the most favorable perception of vaccination, and 5 the most unfavorable. Higher scores represent worse perception of injection. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).
| Scores on a scale | CAB Q4W | RPV Q4W |
|---|---|---|
| Bother of ISRs, Week 1 | 2.23 ± 0.918 | 1.95 ± 0.913 |
| Bother of ISRs, Week 9 | 2.10 ± 0.964 | 1.93 ± 0.891 |
| Acceptance, Week 1 | 2.60 ± 1.173 | 2.28 ± 1.167 |
| Acceptance, Week 9 | 2.30 ± 1.206 | 2.12 ± 1.156 |
The PIN questionnaire is characterized by the dimension scores based on 4 domains including Bother from injection site reactions (ISRs), Acceptability, Leg movement and Sleep categories. The objective of this endpoint is to present analysis of 2 (out of 4) PIN domains: Bother from ISRs and Acceptability. This questionnaire contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. Domain scores were calculated as a mean of all items with the domain. Scores range from 1 to 5,and questions are phrased in such a way as to ensure that 1 always equated with the most favorable perception of vaccination, and 5 the most unfavorable. Higher scores represent worse perception of injection. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).
| Scores on a scale | CAB Q4W | RPV Q4W |
|---|---|---|
| Bother of ISRs | 1.23 ± 0.358 | 1.28 ± 0.377 |
| Acceptance | 1.32 ± 0.570 | 1.46 ± 0.679 |
The PIN questionnaire is characterized by the dimension scores based on 4 domains including Bother from injection site reactions (ISRs), Acceptability, Leg movement and Sleep categories. The objective of this endpoint is to present analysis of 2 (out of 4) PIN domains: Bother from ISRs and Acceptability. This questionnaire contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. Domain scores were calculated as a mean of all items with the domain. Scores range from 1 to 5,and questions are phrased in such a way as to ensure that 1 always equated with the most favorable perception of vaccination, and 5 the most unfavorable. Higher scores represent worse perception of injection. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).
| Scores on a scale | CAB Q4W | RPV Q4W |
|---|---|---|
| Bother of ISRs, Change from Baseline at Week 1 | 0.79 ± 0.843 | 0.41 ± 0.909 |
| Bother of ISRs, Change from Baseline at Week 9 | 0.70 ± 0.931 | 0.41 ± 0.877 |
| Acceptance, Change from Baseline at Week 1 | 1.09 ± 1.100 | 0.58 ± 1.177 |
| Acceptance, Change from Baseline at Week 9 | 0.86 ± 1.145 | 0.44 ± 1.103 |
The PIN questionnaire is characterized by the dimension scores based on 4 domains including Bother from injection site reactions (ISRs), Acceptability, Leg movement and Sleep categories. The objective of this endpoint is to present analysis of 2 (out of 4) PIN domains: Bother from ISRs and Acceptability. This questionnaire contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. Domain scores were calculated as a mean of all items with the domain. Scores range from 1 to 5,and questions are phrased in such a way as to ensure that 1 always equated with the most favorable perception of vaccination, and 5 the most unfavorable. Higher scores represent worse perception of injection. The objective of this outcome measure was to present the data separately for each treatment received (CAB, RPV).
| Scores on a scale | CAB Q4W | RPV Q4W |
|---|---|---|
| Bother of ISRs | -0.17 ± 0.369 | -0.24 ± 0.537 |
| Acceptance | -0.12 ± 0.719 | -0.22 ± 0.888 |
A preference questionnaire was used to assess participant's preference for the subcutaneous injections compared with the gluteal injections. The "Preference" questionnaire included a single item question evaluating preference of HIV treatment. Participants were required to provide their response to Question, which stated "Which injection site do you prefer". The responses included Intramuscular Injections in the buttock, Subcutaneous Injections in the Abdomen and No preference.
| Participants | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Intramuscular Injections in the buttock | 50 |
| Subcutaneous Injections in the Abdomen | 29 |
| No preference | 6 |
A preference questionnaire was used to assess participant's preference for the subcutaneous injections compared with the gluteal injections. The "Preference" questionnaire included a single item question evaluating preference of HIV treatment. Participants were required to provide their response to Question, which stated "Which injection site do you prefer". The responses included Intramuscular Injections in the buttock, Subcutaneous Injections in the Abdomen and No preference.
| Participants | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Intramuscular Injections in the buttock | 61 |
| Subcutaneous Injections in the Abdomen | 21 |
| No preference | 5 |
Collected over All-cause mortality, non-serious adverse events (non-SAEs) and serious adverse events (SAEs) were collected from Week -4 for screening/Gluteal injection phase, from day 1 up to 12 weeks for SC Injection Phase and from Week 12 to Week 20 for Return to IM Gluteal Injection Phase.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CAB LA 400 mg + RPV LA 600 mg - Screening Phase | 1/94 (1.1%) | 1/94 (1.1%) | 33/94 (35.1%) |
| CAB LA 400 mg + RPV LA 600 mg - SC Injection Phase | 0/93 (0%) | 0/93 (0%) | 85/93 (91.4%) |
| CAB LA 400 mg + RPV LA 600 mg - Return to IM Gluteal Injection Phase | 0/93 (0%) | 0/93 (0%) | 38/93 (40.9%) |
| Event | CAB LA 400 mg + RPV LA 600 mg - Screening Phase | CAB LA 400 mg + RPV LA 600 mg - SC Injection Phase | CAB LA 400 mg + RPV LA 600 mg - Return to IM Gluteal Injection Phase |
|---|---|---|---|
| Passed away due to unknown reasonsGeneral disorders | 1/94 | 0/93 | 0/93 |
| Event | CAB LA 400 mg + RPV LA 600 mg - Screening Phase | CAB LA 400 mg + RPV LA 600 mg - SC Injection Phase | CAB LA 400 mg + RPV LA 600 mg - Return to IM Gluteal Injection Phase |
|---|---|---|---|
| Injection site painGeneral disorders | 29/94 | 69/93 | 30/93 |
| Injection site noduleGeneral disorders | 3/94 | 60/93 | 9/93 |
| Injection site erythemaGeneral disorders | 0/94 | 48/93 | 1/93 |
| Injection site swellingGeneral disorders | 0/94 | 29/93 | 1/93 |
| Injection site indurationGeneral disorders | 0/94 | 24/93 | 2/93 |
| Injection site pruritusGeneral disorders | 2/94 | 19/93 | 1/93 |
| Injection site warmthGeneral disorders | 0/94 | 11/93 | 0/93 |
| Injection site haematomaGeneral disorders | 0/94 | 7/93 | 1/93 |
| Injection site bruisingGeneral disorders | 0/94 | 6/93 | 1/93 |
| Injection site discolourationGeneral disorders | 0/94 | 6/93 | 0/93 |
Baseline characteristics presented based on sub-study Safety population. Summary of baseline/demographics for some race/ ethnicity variables are presented as de-identified to prevent risk of participant re-identification.
| Age, Continuous(Years) | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Mean | 42.8 ± 9.43 |
| Sex: Female, Male(Participants) | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Female | 18 |
| Male | 75 |
| Race/Ethnicity, Customized(Participants) | Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg |
|---|---|
| Black or African American | 19 |
| White - White/Caucasian/European Heritage | 63 |
| De-identified | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk.com
Ran from Nov 2022 to primary completion in Sep 2023, 10 months.
Results were first posted in Nov 2024, 1 year 2 months after primary completion.
Of 34 industry-sponsored phase 3 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 27. This study's 10 months is below that.
Counting every sponsor, half of 65 studies reached it within 26 months; a quarter within 19 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cabotegravir · Rilpivirine
Acquired Immunodeficiency Syndrome →